Running title: Acute androgen induced radiosensitization in prostate cancer.
INTRODUCTION
Prostate cancer remains the second leading cause of all cancer related deaths in men in the United states (1) . In particular, in patients diagnosed with high-risk PCa (usually defined as pretreatment PSA > 20 ng/mL, Gleason ≥ 8, or clinical stage ≥ T2c), the 10 year disease free survival rate even under modern therapy is only around 48% (2) . Currently, the standard of care for high-risk or locally advanced PCa involves high dose fractionated radiation therapy in combination with neoadjuvant, concurrent, and long term (approximately 2 years) androgen deprivation therapy (ADT) (2) . Radiation therapy is typically started 2 months after the initiation of ADT, when testosterone levels are at a nadir and the androgen receptor (AR) signaling axis is inactive. The combination of radiation and ADT has led to significant improvements in 10-year progression free survival (47.7% vs. 22 .7%) and prostate cancer specific survival (89.7% vs.
69.6%) compared to radiation therapy alone (2) . Unfortunately, a substantial fraction of men undergoing ADT in combination with radiation therapy experience disease recurrence. In addition, patients also can experience local side effects of dose-escalated radiation treatment, demonstrating the need for more refined therapy approaches that can improve the therapeutic index of radiation based treatment.
Ionizing radiation (IR) results in a large number of cellular insults of which the induction of DNA double strand breaks (DSBs) is the most cytotoxic. Therefore, agents that can induce DNA DSBs or inhibit repair of such breaks can lead to significant and potentially synergistic sensitization to the cytotoxic effects of ionizing radiation (3) . If such DNA damaging agents or DSB repair inhibitors can be directed specifically at prostate cancer cells, then it may be possible to significantly enhance the therapeutic index of radiation based therapy for prostate cancer.
Interestingly, recent reports have shown that DSBs are transiently induced during transcriptional initiation by nuclear hormone receptors and other transcription factors through a mechanism that involves topoisomerase II beta (TOP2B) (4) (5) (6) (7) . In particular, induction of AR transcriptional programs by androgen stimulation, particularly at supraphysiological doses, has been shown to result in widespread, transient DSBs in prostate cancer cells in a TOP2B dependent manner (4) . We hypothesize that these androgen induced DSBs can selectively sensitize AR-positive cells to DNA damaging agents including IR. Here we show that, under castrate conditions, acute activation of AR signaling by androgen stimulation combined with appropriately timed delivery of IR at the peak of DSB formation leads to synergistic growth inhibition of AR-positive prostate cancer cells in vitro and in vivo.
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targeting control siRNA (SMARTpool, Dharmacon) were transfected using RNAiMax transfection reagent (Life Technologies). The following day, cells were washed and medium was replaced with RPMI containing 5% charcoal-stripped FBS. 72 hours after transfection, cells in androgendepleted conditions were exposed to DHT or vehicle control for 6 hours and analyzed by western blotting and neutral comet assays.
Clonogenic survival and cell viability assays. Androgen deprived cells were diluted to the appropriate density in IMDM media containing B27 supplement (Invitrogen) and placed in triplicate into 60-mm culture dishes. DHT was added and 6 h later cells were irradiated with 4 Gy of radiation (Gammacell 40   137 Cs irradiator, Atomic Energy of Canada, LTD., Ottawa, Canada). After the treatments the media was supplemented with the 10% FBS (final concentration) and cells were cultured for 4 weeks. Resulting cell colonies were then stained with a solution of crystal violet in 50% methanol and colonies consisting of ≥ 30 cells were counted. Cell viability was measured using the CellTiter-Blue assay (Promega) according to the manufacturer's protocol. In brief, androgen-deprived LNCaP cells were harvested and exposed to 0 or 4Gy ionizing radiation, plated in 96-well plates in triplicate at 1x10 3 
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using ImageJ (National Institute of Health, Bethesada, USA) and the telometer plugin. For immunohistochemical labeling of γH2A.X, slides were steamed in HTTR buffer (Dako, Carpinteria, CA) and primary antibodies (07-164, Millipore) were applied at 1:4000 dilution at room temperature for 1 h. Immunostaining for caspase 3 was performed after pretreatment in citrate buffer followed by overnight incubation with anti-cleaved caspase 3 specific antibodies at 1:1000 dilution at 4° C (5A1E, Cell Signaling Technology, Beverly, MA). Immunocomplexes were visualized using PowerVison + Poly HRP from ImmunoVision Technologies Co (Norwell, MA, USA) with DAB as the chromogen. Figure 2) . In addition, induction of DSBs required the agonistic action of DHT on the AR, since treatment with a potent AR-antagonist (enzalutamide) did not result in an increase in comet tail moments ( Figure 2C, Supplementary Figure 2C) .. These observations strongly suggest that androgen induced DSBs are functionally dependent on androgen receptor mediated signaling and TOP2B activity. Since androgen stimulation can modulate cell cycle kinetics in prostate cancer cells, we investigated the possibility that cell cycle progression, particularly to S-phase or mitosis which can each be associated with replicative stress, could contribute to androgen induced DSB. We pretreated LAPC4 cells with lovastatin to induce a pharmacological G1 arrest. Lovastatin and control vehicle pre-treated cells were then stimulated with DHT and androgen induced DSBs were determined by γH2A.X staining ( Figure   2D ). Pharmacological cell cycle arrest did not change the levels of androgen induced γH2A.X foci, suggesting that cell cycle progression is not required for androgen mediated DSB formation.
RESULTS

Androgen induced transient
Furthermore, 6 h after DHT treatment, when highest levels of DSBs were observed, both LNCaP and LAPC4 cells did not show a significant increase in cell proliferation as measured by EdU incorporation ( Figure 2E ) and LNCaP did not show a change in S-phase fractions ( Figure 2F ) as compared to control treated cells. These results strongly suggest that androgen exposure of prostate cancer cells leads to a dose dependent induction of DSBs, which is independent of cell cycle progression but dependent on AR and TOP2B.
Short-term androgen stimulation sensitizes AR positive prostate cancer cells to IR.
IR is known to cause a diverse array of cellular damage. The majority of the lethal effects are the consequence of IR induced DSBs, which are generated in a dose dependent manner (11). Since androgen stimulation could induce DNA damage in androgen-deprived prostate cancer cells (Figure 1 and 2 ) (4), we aimed to determine if exposure of AR-positive cells to supraphysiological levels of androgens for 6 hours (the point of maximal induction of DSBs, but absence of significant androgen mediated cell cycle progression as shown in Figure 1 and 2) could synergize with IR.
We used two androgen dependent prostate cancer cell line models, LNCaP and LAPC4. Cells were deprived of androgens and cell viability and clonogenic survival assays were performed after short-term androgen exposure followed by IR (Figure 3) . Whereas DHT treatment alone did not alter clonogenicity and cell viability, pre-stimulation of cells with 100 nM DHT for 6 h followed by 4
Gy radiation significantly decreased cell survival compared to IR alone (Figure 3) . Similar to the induction of DSBs, a dose dependency was observed and only high doses of DHT (> 1 nM) 
DHT-mediated effect was only observed in AR-positive cells (LNCaP and LAPC4) and not in ARnegative PC3 cells (Supplementary Figure 3) . These in vitro data demonstrate that androgen deprivation followed by short term androgen exposure prior to IR shows a synergistic effect on reducing tumor cell viability, suggesting that altered timing of radiation to a point at which androgen induced DNA breaks are greatest could improve therapeutic outcomes. Furthermore, the androgen induced radiosensitization effect is AR dependent and occurs with supraphysiological doses of DHT.
Rapid increase of androgens to supraphysiological levels triggers DSBs and apoptosis in vivo.
To assess whether androgen stimulation of androgen deprived prostate cancer cells would produce DSBs in vivo, we castrated mice that were bearing established LAPC4 xenograft tumors in their flanks. Two weeks after castration, animals received subcutaneous injection of 10 μg/g DHT.
DHT levels were then serially determined in serum and in tumor xenograft tissues obtained from tumor biopsies (Figure 4) . DHT injection resulted in a sharp increase in both tumor and serum DHT levels and peaked around 6 h post injection. Importantly, supraphysiological levels of DHT were reached in both xenograft tissues and serum (peak levels, 17.8 nM and 70.1 nM for tissue and serum respectively) ( Figure 4A ). Xenograft tumor biopsies were analyzed for evidence of DHT induced DSB and induction of apoptosis using immunohistochemical detection of γH2A.X and cleaved caspase 3 respectively (Figure 4A and B) . In line with our previous in vitro findings, we observed an increase in γH2A.X foci over time, with highest levels detected after 24 h (Figure 4B) . Importantly, γH2A.X foci returned to near baseline levels 72 h after treatment, supporting the transient nature of the androgen induced DSBs also in vivo, similar to our previous observations in vitro (Figure 1) . The in vivo kinetics appeared to be different compared to the kinetics observed in vitro, likely due to the more complex pharmacokinetics of dihydrotestosterone in vivo. It is worth noting that in this model androgen stimulation alone resulted in a measurable increase in apoptosis in tumor cells, suggesting that androgen induced breaks can potentially be sufficient to induce cell death in at least a subset of cells ( Figure 4C ). This result might provide an explanation for previous observations showing that in vivo growth rates of several prostate cancer cell line models are inhibited by high dose androgens (12) (13) (14) . Androgen and IR synergize in vivo in controlling prostate cancer xenograft growth A combination of ADT together with fractionated IR is currently the standard of care for locally advanced prostate cancer. IR is usually given when testosterone levels are at a nadir and ADT is continued for a period of time after radiation. To mimic a clinically relevant treatment scenario in an in vivo model of human prostate cancer we used the two androgen responsive cell lines LAPC4 and LNCaP, which show robust response to IR (Supplementary Figure 3) . Xenografts of LNCaP and LAPC4 cells were established in castrate nude mice in which testosterone levels were controlled by a silastic testosterone containing implant. When tumors reached a consistent size, the implant was removed to achieve castrate testosterone levels. After 16 days of castration, xenograft tumors received either no IR (control) or a single dose of 8 Gy IR during castration (traditional) or 12 h after (experimental) re-administration of the testosterone implant producing an acute peak of testosterone levels ( Figure 5A) . Tumor size was then evaluated longitudinally over a period of 8 weeks and time to progression (defined as > 4x tumor volume) was calculated.
Tumors that were not irradiated showed a rapid progression ( Figure 5D and E), as did tumors that were irradiated without androgen manipulation (Supplementary Figure 4) . Most interestingly, mice that received testosterone implants 12 h prior to IR showed smaller tumor sizes ( Figure 5B and C) and a significantly smaller fraction reached the progression benchmark ( Figure 5D and E) compared to mice that received IR during castration when testosterone levels were at a nadir ( Figure 5B, p < 0.01 and C, p < 0.05). These results suggest that, in the setting of ADT, stimulation with supraphysiological androgen levels prior to IR may improve treatment outcomes for radiation therapy of prostate cancer.
DISCUSSION
Given that androgens are known to fuel prostate cancer growth and survival, androgen suppression has been a mainstay of therapy for advanced prostate cancer. and in vivo prostate cancer models demonstrating that, high-dose androgens can decrease tumor cell growth and viability (12) (13) (14) . Furthermore, several proof-of principle clinical trials have established that supraphysiologic androgens can be safely given to patients with recurrent or metastatic prostate cancer (14, 19, 20) . More encouragingly, a number of case reports and a recent proof-of-principle trial have shown dramatic reduction of disease burden after androgen treatment in patients with castration resistant metastatic disease (13, 14, (21) (22) (23) . Taken 
signaling can influence the cell cycle. In particular, androgen stimulation of androgen depleted cells induces proliferation and cell cycle entry (28) ; therefore modulation of cell cycle kinetics may be responsible for differential radiosensitization. Here we show that short-term androgen exposure does not result in significant changes in cell cycle distribution of prostate cancer cells. Furthermore, androgen induced breaks can also be induced in cells which have been pharmacologically arrested in G1. Therefore androgen-induced changes in cell cycle kinetics is an unlikely explanation for the observed increased sensitization at early time points after androgen stimulation.
In previous preclinical and clinical studies, hormonal treatment was used to synchronize cells in vulnerable cell cycle phases for subsequent radiation and chemotherapies (29) . The approach outlined here is fundamentally different from these studies. Activation of hormonal signaling is not used for cell cycle synchronization; in fact at the time points used in the present study no changes in cell cycle progression are detected, but a different mechanism that likely relies on a cell-cycle independent induction of DSBs is exploited. It is important to highlight that the timing of hormone exposure, induction of DSBs and resulting radiosensitization needs to be carefully examined in further pre-clinical and clinical studies in order to investigate the potential to apply this paradigm clinically for radiosensitization of human prostate cancers.
Additionally, the in vitro and in vivo studies (performed in athymic nude mice) carried out here are largely focused on studying the effect of high-dose androgens and IR on cancer cell intrinsic DNA damage, response, and growth/survival. Interestingly, since it has been observed in previous studies that both androgen treatment and IR can have important effects on tumor microenvironmental, and host immune responses (30) (31) (32) (33) (34) , it will be important to examine these cancer cell extrinsic mechanisms during further pre-clinical and clinical studies investigating the effectiveness of acute androgen stimulation to sensitize to radiation therapies.
An important aspect of the above described androgen induced breaks is that this mechanism relies on the induction of androgen signaling. It is therefore possible that multiple cycles of androgen depletion followed by androgen stimulation would lead to DSB induction and radiosensitization at each cycle, and thus better control. Such an androgen cycling schema, in which a patient undergoing ADT would receive multiple pulses of androgen boosts followed by IR could be implemented into the currently used fractionated radiation treatment regimens. More generally, the observation that androgen stimulation of androgen deprived cells selectively sensitizes AR-positive cells to IR has important implications for prostate cancer radiation therapy.
Many normal pelvic tissues that are exposed to IR during external beam radiation therapy of the 
13
prostate do not express AR. Therefore, the above described approach should improve therapeutic index by selectively sensitizing prostate cancer cells to IR without sensitizing normal pelvic tissues and enhancing toxicity. One important consequence of this unique tissue specific sensitization could be to allow for a reduction of the IR total dose, improving direct radiation related quality of life outcomes. Furthermore, as noted in previous studies, intermittent high-dose androgen therapy can significantly improve the overall quality of life of patients undergoing ADT (14) .
The data presented here could be viewed as contradictory to two previously published studies that suggest that anti-androgen treatment results in a reduced expression of androgen regulated DNA repair genes and decreased classical non-homologous end-joining capacity (9,10).
These observations suggest that androgen regulated DNA repair genes are involved in the immediate repair of DNA damage inflicted by IR. It is however very important to note that the androgen-induced transcriptional up-regulation of DNA repair proteins observed in those studies was not apparent in the acute time scales where we observe maximal DSB formation (0-12 hours after stimulation), but appears to be a later response occurring after 24 hours, concomitant with the resolution of DSBs (see Figure 1 and Supplementary Figure 1) . We speculate that such upregulation of DNA repair genes by AR signaling at later time points may represent a programmed mechanism occurring as a response to the propensity for androgen signaling to induce DNA damage. Therefore, the timing of androgen treatment and IR is critical. Here we show that administration of IR in this vulnerable phase shortly after DHT treatment results in reduced cancer cell growth both in vivo and in vitro. In this phase, when androgen induced DSBs are at a high level and induction of androgen responsive repair pathways has not fully developed, a window for a true synergistic effect between androgen and IR induced DSBs seems to exist. Furthermore, here we show that supraphysiologic levels of DHT are required to robustly induce DSBs. In both studies by Goodwin et al. and Polkinghorn et al. lower concentration of androgens are used, which might have different effects on cancer cell survival (9, 10) . Additionally, in the paradigm proposed here, high-dose androgen pulses would be given during IR therapy in the context of long-term ADT; patients would return to castrate hormone levels in between pulses of high-dose androgen, and during adjuvant hormonal therapy after fractionated IR treatment. Thus, the paradigm presented here would still take advantage of the known benefit of neoadjuvant and adjuvant ADT, the mechanistic basis of which has been attributed to inhibition of the reciprocal link between IR induced AR signaling, and androgen induced DNA damage response (9) (10) (11) (16) (17) (18) . Therefore, the present study represents an important extension of our previous knowledge on androgen receptor signaling and DNA damage. The observations in this study and these previous studies are mutually supportive and suggest a time and dose dependent differential response of androgen signaling in prostate cancer cells exposed to IR. 
